Heart-Kidney drug trial halted early – what happened?
NCT ID NCT06611423
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested an experimental drug called AZD3427 in 10 people with heart failure and reduced kidney function. The goal was to see if the drug could improve blood flow to the kidneys, measured with a special PET scan. However, the study was terminated early, so we don't have clear results on whether the drug works or is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD3427
- What this could lead to
- If it worked, this could point toward a new way to protect kidney function in people with heart failure.
- What could go wrong
- This was a very small, early-phase trial that was terminated early, so we have little data. The drug may not improve kidney blood flow or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Solna, 171 64, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a damaged kidney change how antibiotics work?
- Can a valve fix unlock better heart failure drugs?
- Can a new pill help a failing heart pump better?
- Can kidney health change how a new drug works?
- Kidney function may change how D-2570 works in the body
- Iron showdown: IV vs. pills for heart failure fatigue